AMY2A

Across TCGA pan-cancer cohorts, AMY2A Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AMY2A data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher AMY2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AMY2A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

READ, BRCA, and HNSC are the cancer types where AMY2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	All	0.234	0.845	<.001	39	view →
BRCA	OS	Median	All	0.027	0.963	<.001	36	view →
HNSC	OS	Median	All	0.146	0.768	<.001	18	view →
UCEC	DFS	Median	All	1.000	0.632	.016	16	view →
SKCM	OS	Median	III,IV	0.216	0.721	.001	9	view →
ESCA	OS	Median	All	0.222	0.680	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AMY2A–READ (OS)

Open the READ breakdown →